Interactive Savings Map - Find out how much your state saved from generic and biosimilar medicines.
  • GRx+Biosims 2023
    Be Part of the GRx+Biosims 2023 Experience
    Early Bird Special - Sign up by May 31 and save $100 on a full-pass registration.
  • Fireside chat with Mark Cuban at Access! 2023
    "You guys make such a huge difference that you don't get credit for."
    Mark Cuban on generic medicines.
  • AAM's Prescription for State Savings
    AAM’s Prescription for State Savings
    State lawmakers can take meaningful action to lower brand prescription drug costs with the Prescription for State Savings. AAM outlines several solutions states could pursue.
  • Study Finds Middlemen Increasingly Block Patient Access to New Generics
    New report shows that middlemen like health plans and pharmacy benefit managers (PBMs) increasingly block patient access, delaying coverage of new generics in favor of higher-priced brand drugs with high rebates.
  • 2021 Savings for Patients by Condition
    Generic and biosimilar medicines improve access and affordability for the millions of people with illnesses like asthma, arthritis, heart disease, and depression. Learn more and download fact sheets about the savings by common patient conditions.
  • AAM 2022 U.S. Generic and Biosimilar Medicines Savings Report
    2022 U.S. Generic & Biosimilar Medicines Savings Report
    Savings continue to grow with $373B saved in 2021 the U.S. health care system, including patients, employers, and taxpayers. With 91% of Rx filled and only 18% of Rx drug spending, findings reinforce the critical importance of the generic and biosimilar industry to America’s patients.
  • AAM Voices of Access
    AAM Voices of Access
    Physicians, pharmacists, patients and caregivers across the country trust generics and biosimilars. Here are their stories, in their own words—along with perspectives from health care professionals and the AAM team.

Our Brands and Campaigns

Association for Accessible Medicines


Sign-up for Updates

Receive relevant industry news, event information and the latest resources on biosimilars and generic medicines.

Stay Connected

For the latest updates, follow us on social media.